enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
Source ↗
👁 0
💬 0
54% complete response (CR) rate at any time; 43% six‑month CR rate
Low rate of progression to muscle-invasive or higher disease (3.2%)
Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), nearly all of which were mild
Low percentage of patients experienced TRAEs leading to treatment interruption (2.4%) or discontinuation (2.4%)
Kaplan-Meier estimate of 12-month CR rate is 25%
enGene to host webcast to discuss results today, May 7, 2026, at 8:00 a.m.
Low rate of progression to muscle-invasive or higher disease (3.2%)
Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), nearly all of which were mild
Low percentage of patients experienced TRAEs leading to treatment interruption (2.4%) or discontinuation (2.4%)
Kaplan-Meier estimate of 12-month CR rate is 25%
enGene to host webcast to discuss results today, May 7, 2026, at 8:00 a.m.
Comments (0)